



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11) EP 0 956 855 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
17.11.1999 Bulletin 1999/46(51) Int. Cl. 6: A61K 31/52, C07D 473/06,
C07D 473/10

(21) Application number: 98201323.7

(22) Date of filing: 24.04.1998

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE

Designated Extension States:
AL LT LV MK RO SI

(71) Applicants:
• K.U. Leuven Research & Development
3000 Leuven (BE)
• Pfleiderer, Wolfgang
78464 Konstanz (DE)


(72) Inventors:
• Waer, Mark Jozef Albert
3001 Heverlee (BE)
• Herdevijn, Piet André Maurits Maria
3111 Rotzelaar/Wezemaal (BE)
• Pfleiderer, Wolfgang
78464 Konstanz (DE)

(74) Representative: Bartelds, Erik
Arnold & Siedsma,
Advocaten en Octrooigemachtigden,
Sweetinckplein 1
2517 GK Den Haag (NL)

(54) Immunosuppressive effects of 8-substituted xanthine derivatives

(57) The invention relates to a novel use of 8 substituted xanthine derivatives for the manufacture of a medicament for the treatment of auto-immuno disorders.

The invention relates in particular to the use of a xanthine derivative of general formula (I):



substituted or unsubstituted amino group; aliphatic chain with 1 to 3 carbon atoms; halogenated aliphatic chain with 1 to 3 carbon atoms; aliphatic chain containing ether functions, acids, esters, amides, substituted or unsubstituted amines having 1 to 3 carbon atoms, nitro, sulfonamides or a combination of these functional groups with a maximum length of the chain of 12 atoms,

or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of auto-immuno disorders.

wherein:

R₁, R₂ and R₃ are independently hydrogen, saturated or unsaturated aliphatic chains which may be straight or branched having 1 to 6 carbon atoms;
X and Y are independently oxygen or sulfur;
Z₁ is selected from the group comprising a thiényl, furanyl, cyclopentyl, phenyl or a substituted by Z₂ or unsubstituted phenyl; wherein Z₂ is selected from the group comprising phenyl, sulfonic acid, unsubstituted or N-substituted sulfonamide with substituents such as alkyl, aminoalkyl where the amino group may be substituted itself with lower alkyl groups bearing 1 to 4 carbon atoms; nitro; halogen

EP 0 956 855 A1

Printed by Xerox (UK) Business Services
2.16.73.6

EP 0 956 855 A1

Description

[0001] The invention relates to a novel use of 8 substituted xanthine derivatives for the manufacture of a medicament for the treatment of auto-immuno disorders.

5 [0002] Methylxanthines, for example pentoxifylline (PTX) are known having immunosuppressive effects in vitro.


[0003] Several types of 8-substituted xanthine derivatives have been publicized, for example K.A. Jacobson et al. *J. Med. Chem.* 1993, 36, 2639-2644; K.A. Jacobson et al. *Biochem. Pharmacol.* 1988, 37, 3653-3661; K.A. Jacobson et al. *J. Med. Chem.* 1989, 32, 1873-1879.

10 [0004] Recently (Lin Y. et al. *Transplantation* 63 (1997) it has been found that the co-medication of an immunosuppressive compound such as cyclosporine A (CyA) or FK506 or RPM (rapamycin) with a methyl xanthine derivative, in particular A802715 (7-propyl-1(5-hydroxy-5-methylhexyl)-8-methylxanthine) leads to a superadditive increase in the immunosuppressive action.

[0005] The immunosuppressive effect of cyclosporine A (CyA) is already known since 1972. However, due to its nephrotoxicity and several other side effects CyA has not been able to establish itself as the optimal and final drug of choice.

15 [0006] The present invention relates to a novel use of 8-substituted xanthine derivatives and their pharmaceutical salts, possessing unexpectedly desirable pharmaceutical properties, i.e. are immunosuppressive agents.

[0007] The invention demonstrates a novel use of xanthine derivatives of the formula (I):



30 wherein:

R₁, R₂ and R₃ are independently hydrogen, saturated or unsaturated aliphatic chains which may be straight or branched having 1 to 6 carbon atoms;

X and Y are independently oxygen or sulfur;

35 Z₁ is selected from the group comprising a thiényl; furanyl; cyclopentyl or a substituted by Z₂ or unsubstituted phenyl; wherein Z₂ is selected from the group comprising phenyl; sulfonic acid; unsubstituted or N-substituted sulfonamide with substituents such as alkyl, aminalkyl where the amino group may be substituted itself with lower alkyl groups bearing 1 to 4 carbon atoms; nitro; substituted or unsubstituted amino group; aliphatic chain with 1 to 3 carbon atoms; halogenated aliphatic chain with 1 to 3 carbon atoms; aliphatic chain containing ether functions, acids, esters, amides, substituted or unsubstituted amines having 1 to 3 carbon atoms, nitro, sulfonamides or a combination of these functional groups with a maximum length of the chain of 12 atoms.

40 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of auto-immuno disorders.

45 [0008] The invention further relates to a combination preparation, containing 1) cyclosporin A or FK506 or rapamycin, 2) at least one 8-substituted xanthine derivative of formula (I), and optionally a pharmaceutical excipient, for simultaneous, separate or sequential use in (auto)immune disorders.

[0009] Hereunder the effects of the 8-substituted xanthine derivatives on the lymphocyte activation are elucidated and are compared with non-substituted xanthine derivatives (see table I, compound 1,2,3,4,5,22,23,24,25,26, and 50 67,68,69,70,71).

[0010] Table I summarizes the tested compounds. These xanthine derivatives were obtained as follows:

Compound number 8, 10, 12, 14, 21, 36, 37, 38, 47, 48, 50, 51, 79, 83

K.A. Jacobson et al. *J. Med. Chem.* 1993, 36, 2639-2644;

55 9, 11, 13, 30, 31, 39, 40, 41, 42, 43, 125

K.A. Jacobson et al. *Biochem. Pharmacol.* 1988, 37, 3653-3661;


EP 0 956 855 A1

15, 17, 18, 28, 29, 33, 34, 35, 44, 45, 46, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 78, 80, 81
 K.A. Jacobson et al. J. Med. Chem. 1989, 32, 1873-1879;

[0011] Compound numbers 1, 2, 3, 4, 5, 22, 23, 24, 67, 68, 82, 112, 113, 114, 116, 117, 118, 119 (table I and II) were obtained by the following procedure for the alkylation of xanthine derivatives.

[0012] 0.01 mol of a xanthine derivative (1a, 2a, 3a, 4a, 5a, 67a, 68a, 82a, 112a, 113a (114a), 116a (117a), 118a (119a)). (The origin of these compounds is as follows: 1a Theobromin, commercially available FLUKA AG; 2a W. Traube, Ber. Deut. Chem. Ges. 33, 3085 (1900); 3a G. Elion, J. Org. Chem. 27, 2478 (1962); 4a W. Hutzlerlaub, W. Pfeiderer, Liebigs Ann. Chem. 1979, 1847; 5a Xanthin, commercially available FLUKA AG; 67a W. Hutzlerlaub, W. Pfeiderer, Liebigs Ann. Chem. 1979, 1847; 68a P.G. Kjellin, C.G.A. Persson, Eur. Pat. Appl. 10 531; C.A. 94, P 15773 u; 82a K.A. Jacobson, D. Shi, C. Gallo-Rodriguez, M. Manning, C. Müller, J.W. Daly, J.L. Neumayer, L. Kirasis, W. Pfeiderer, J. Med. Chem. 36, 2639 (1993); 112a H. Goldner, G. Dietz, E. Carstens, Liebigs Ann. Chem. 691, 142 (1966); 113a M.T. Shamim, D. Ukena, W.L. Padgett, J.W. Daly, J. Med. Chem. 32, 1231 (1989)) (see table II) were suspended or dissolved in DMF (60 ml) at room temperature and then under stirring K_2CO_3 (6 g per N-H function) and the alkylating agent (methyl iodide, allyl iodide, propargyl bromide, n-propyl iodide, benzyl bromide, 2-chlorobenzyl bromide, 4-bromobutanoic acid, 5-bromopentanoic acid, ethyl 4-bromobutanoate) (0.015 mci per N-H) function added. The mixture was stirred at room temperature for 15 h, then the insoluble inorganic salts filtered off by suction and the filtrate evaporated in vacuum at 50°C to a syrup. The residue was treated with H_2O forming a colorless solid. The precipitate was collected and purified by recrystallization from $H_2O/EtOH$ mixtures to give colorless crystals of 1, 2, 3, 4, 5, 67, 68, 82, 112, 113, 114, 116, 117, 118, 119.

[0013] Compound numbers 16, 52, 53, 54, 69, 70, 71, 115, 116a (117a), 118a (119a) (table I and III) were obtained by a procedure for the cyclization of 5-acylamino-6-aminouracils



[0014] The 5-acylamino-6-aminouracil (16a, 52a, 53a, 54a, 69a, 70a, 71a, 115a, 116b, 118b) (0.01 mol) was heated in a mixture of 2 NaOH (50 ml) and EtOH (10 ml) under reflux for 30 min. The hot solution was acidified by AcOH whereby a colorless precipitate separated. The solid was collected after cooling, dried and then purified by recrystallization from EtOH, DMF or by reprecipitation from alkaline solution by addition of AcOH.

General procedures for the synthesis of 5-acylamino-6-amino-uracils (16a, 52a, 53a, 54a, 69a, 70a, 71a, 115a, 116b, 118b) (table IV).

45 [0015]

- a) 0.01 mol of the N-substituted 5,6-diaminouracil (69b, 70b, 71b) was heated in formic acid (20 ml) for 15 min under reflux. The reaction mixture was evaporated to dryness and the residue recrystallized from water to give colorless crystals (69a, 70a, 71a). Yield: 75-90%.
- 50 b) 0.01 mol of the N-substituted 5,6-diaminouracil (52b, 53b, 116c) was treated with 0.012 mol of the appropriate acyl chloride (p-nitrobenzoyl chloride, p-biphenyl-4-carbonyl chloride, p-chlorobenzoyl chloride, p-aminobenzoyl chloride) in abs. pyridine (20 ml) with stirring at room temp. for 3 hours. It was evaporated, the residue treated with water and the resulting precipitate collected by suction. Recrystallization from EtOH/H₂O yielded 70-90% of colorless crystals (52a, 115a, 53a, 54a, 116b, 118b).
- 55 c) 0.01 mol of the N-substituted 5,6-diaminouracil (16b) was suspended in EtOH (100 ml), then subsequently added 0.011 mol of the appropriate acid (p-sulfamoylbenzoic acid) and 0.012 mol of the condensing agent (dicyclohexylcarbodiimide), N-dimethylaminopropyl-N'-ethylcarbodiimide hydrochloride). The mixture stirred at room temp. for 2 hours, the precipitate filtered off and purified by recrystallization from EtOH to give colorless crystals

EP 0 956 855 A1

(16a). Yield: 80-90%.

General procedure for the synthesis of N-alkyl-5,6-diaminouracil (16b, 52b, 53b, 69b, 70b, 71b, 116c) (table V).

5 [0016]

a) 0.05 mol of 6-amino-3-methyl-1-neopentyuracil (69c), 6-amino-1,3-dimethyluracil (52c), 6-amino-1,3-di-n-propyluracil (53c), 6-amino-1-isopropyl-3-methyluracil (71c), 6-amino-1-n-propyluracil (116d) and 6-amino-1,3-di-n-propyl-2-thiouracil (16c), respectively, were suspended in a mixture of water (100 ml) and EtOH (20 ml) and heated to 50°C. Then NaNO₂ (4 g) was added and the stirring mixture acidified by dropwise addition of AcOH (5 ml) whereby intermediary solution with strong coloration takes place. A red to violet coloured precipitate consisting of the corresponding 5-nitroso derivative was formed. The solid was collected after cooling (85-90%) and used directly for reduction to the anticipated N-alkyl-5,6-diaminouracil (69b, 52b, 53b, 71b, 116c, 16b). 0.05 mol of the 6-amino-N-alkyl-5-nitrosouracil derivative was added under stirring to a warm solution (50°C) of ammonium sulfide (25 ml) and then the temperature raised to 80°C for 15 min. On cooling the resulting precipitate was filtered off by suction, washed with water and little MeOH and then dried in a vacuum desiccator to give 75-90% of colorless to yellowish crystals.
b) 6-Amino-5-methylamino-1-neopentyuracil (70b). 6-Amino-1-neopentyuracil (70c) (3.94 g, 0.02 mol) was treated in AcOH (40 ml) at 80°C in presence of NaOAc x 3 H₂O (2.6 g, 0.02 mol) with bromine (3.2 g, 0.02 mol) by dropwise addition. After 2 hours was cooled, the precipitate (75%) collected, washed with water and dried. 6-Amino-5-bromo-1-neopentyuracil (2.76 g, 0.01 mol) was then stirred in a 40% aqueous methylamine solution (80 ml) at room temp. for 2 days. The mixture was evaporated to half its volume and the precipitate collected. Washing with water and drying in a desiccator yielded 2.05 g (90%) of 70b. M.P. 217-220°C.


25 Syntheses of N-alkyl-6-aminouracils.

[0017] 6-Amino-1-neopentyuracil (70c). N-neopentylurea (13.0 g, 0.1 mol) and ethyl cyanoacetate (10 ml) were heated in 4N NaOEt (100 ml) for 4 hours under reflux. The reaction mixture was evaporated to dryness, the residue treated with water (100 ml) and then acidified with AcOH to pH 4-5 to form a colorless precipitate. Yield: 11.2 g (59%).
[0018] 6-Amino-3-methyl-1-neopentyuracil (69c). 6-Amino-1-neopentyuracil (90c) (5.9 g, 0.03 mol) were dissolved in 1 N NaOH (50 ml) and then under vigorous stirring dimethylsulfate (3.9 ml, 0.039 mol) dropwise added at room temp. A precipitate separated and was collected after 2 hours. After washing with water and drying in a vacuum desiccator resulted 5.76 g (91%) of colorless crystals.
[0019] 6-Amino-3-methyl-1-n-isopropyluracil (71c). 6-Amino-1-isopropyluracil (16.9 g, 0.1 mol) were dissolved in 1 N NaOH (120 ml) and then at room temp. dimethylsulfate (12 ml, 0.12 mol) dropwise added with vigorous stirring. After 1 hour the precipitate was collected, washed with water and dried at 50°C in high vacuum to give 15.1 g (82%) of chromatographically pure, colorless crystals.
[0020] 6-Amino-1-n-propyluracil (116d). N-n-propylurea (20.4 g, 0.2 mol) and ethyl cyanoacetate (20 ml) were heated in 8 N NaOMe (200 ml) for 3 hours under reflux. The reaction mixture was evaporated, the residue treated with 100 ml of water and acidified with AcOH to pH 4 to give 23.7 g (70%) of colorless crystals.
[0021] 6-Amino-1,3-di-n-propyl-2-thiouracil (16c). To a mixture of cyanoacetic acid (10 g) and acetic anhydride (50 ml) was added N,N'-di-n-propylthiourea (16 g, 0.01 mol) and stirred at 60°C for 4 hours. It was evaporated to dryness, the residue treated with 30% NaOH (100 ml) for 30 min, then diluted with water (100 ml) and the precipitate collected. Recrystallization from EtOH/water gave 18 g (79%) of yellowish crystals. The same procedure and started from N,N'-dimethylurea or N,N'-di-n-propylurea yielded 6-amino-1,3-dimethyluracil (52c) and 6-amino-1,3-di-n-propyluracil (53c) respectively as colorless crystals.
[0022] Compoundnumbers 25 and 26 (table I and table III) were obtained by a general procedure for the synthesis of 1-(5-hydroxyhexyl)panthines.

50

55

EP 0 956 855 A1



[0023] 3,7-Dialkyl-1-(hexan-5-onyl)xanthine (2 mmol) was dissolved in MeOH (15 ml) and then treated under stirring with NaBH₄ (0.1 g) overnight. The mixture was evaporated to dryness, the residue diluted with H₂O, then extracted several times with CHCl₃. The CHCl₃ layer was dried over Na₂SO₄, filtered and the filtrate again evaporated to give a chromatographically pure solid. The solid was stirred in n-hexane for 1 h, then filtered by suction and dried in a vacuum desiccator to give a colorless crystal powder.

[0024] Compounds 19, 20 and 66 were obtained by methylation of 55, 57 and 64 respectively. 0.01 Mol of the purine 55, 57 and 64, respectively, was dissolved in DMF (120 ml) by warming. After cooling to room temperature K₂CO₃ (7 g) and methyl iodide (2 ml) were added and then the mixture stirred for 8 hours. The solution was then diluted with H₂O (150 ml) and after cooling the precipitate collected, washed with water and dried. Recrystallization from EtOH/H₂O gave colorless crystals in 75-90% yield. M.p. 198°C (19), 296°C (20) and 197°C (66).

[0025] The synthesis of compound 32 is based on compound 33, which is described in literature [K.A. Jacobson, K.L. Kirk, W.L. Padgett, J.W. Daly, J. Med. Chem. 1985, 28, 1334]. Compound 33 (2.14 g, 0.005 mol) was suspended in abs. pyridine (50 ml) and then under stirring chlorosulfonic acid (4 ml) added dropwise. It was heated to 50°C with stirring for 12 hours. The reaction mixture was evaporated in vacuum, coevaporated twice with EtOH and the residue recrystallized from H₂O/EtOH to give 1.95 g (77%) of 32 of a colorless crystal powder. M.p. 245°C.

Materials and methods

[0026] Various models may be used for testing an immunosuppressive effect. In vivo, for example, different transplantation models are available. They are strongly influenced by different immunogeneticities, depending on the donor and recipient species used and depending on the nature of the transplanted organ. The survival time of transplanted organs can thus be used to measure the suppression of the immune response. In vitro, there exist also various models. The most used are lymphocyte activation tests. Usually activation is measured via lymphocyte proliferation. Inhibition of proliferation thus always means immunosuppression under the experimental conditions applied. There exist different stimuli for lymphocyte activation:

- coculture of lymphocytes of different species (MLR = mixed lymphocyte reaction): lymphocytes expressing different minor and major antigens of the HLA-DR type (= allogens) activate each other non-specifically.
- CD3 assay: here there is an activation of the T-lymphocytes via an exogenously added antibody (OKT3). This antibody reacts against the CD3 molecule located on the lymphocyte membrane. This molecule has a costimulatory function. The interaction anti-CD3 [= OKT3]-CD3 results in T-cell activation which proceeds via the Ca²⁺/calmodulin/calcineurin system and can be inhibited by CyA.
- CD28 assay: here specific activation of the T-lymphocyte goes also via an exogenously added antibody against the CD28 molecule. This molecule is also located on the lymphocyte membrane, and delivers strong costimulatory signals. This activation is Ca²⁺-independent and thus cannot be inhibited by CyA.
- IL-2R assay: here activation of the lymphocyte occurs via the exogenously added cytokine IL-2 which binds to the IL-2 receptor (IL-2R) that is located on the lymphocyte membrane of prestimulated T cells. This activation is also Ca²⁺/cAMP-independent and cannot be inhibited by CyA.

Reagents

[0027] All derivatives were dissolved in 0.5 ml DMSO and further diluted in culture medium before use in in vitro experiments. The culture medium consisted of RPMI-1640 + 10% FCS.

EP 0 956 855 A1

Mixed Lymphocyte Reaction

- [0028] Peripheral blood mononuclear cells (PBMC) were isolated from heparinized peripheral blood by density gradient centrifugation over Lymphoprep (Nycomed, Majorstua, Norway). Allogeneic PBMC or EBV-transformed human B cells [RPMI1788 (ATCC name CCL156)] which strongly express B7-1 and B7-2 were used as stimulator cells after irradiation with 30 Gy. MLR was performed in triplicate wells. After 5 days incubation at 37°C, 1 μ Ci [3 H]-thymidine was added to each cup. After a further 16 hours incubation, cells were harvested and counted in a β -counter.
- [0029] The percent suppression of proliferation by drugs was counted using the formula:

$$10 \quad \text{Per cent inhibition} = \frac{(\text{cpm+drugs}) - \text{cpm Cult.Med.}}{(\text{cpm+drugs}) - \text{cpm Cult.Med.}} \times 100$$

T cell purification

- [0030] T cells were purified by removing non-T cells. Briefly, monocytes were removed by cold agglutination. The resulting lymphoid cells were further purified by a cell enrichment immunocolumn [Collect Human T (Biotex, Edmonton, Alberta, Canada)] by a process of negative selection. More than 95% of the B cells were removed with this procedure. After depletion, the resulting T cell preparation was highly purified explaining these cells could not be activated by PHA or rIL-2 alone at concentrations capable of stimulating PBMC prior to deletion.

Measurements of T cell proliferations induced by anti-CD3 mAb + PMA or anti-CD28 mAb + PMA

- [0031] Highly purified T cells (10^6 /ml) were stimulated by immobilized anti-CD3 or anti-CD28 mAb in the presence of PMA. Anti-CD3 mAb (CLB-CD3; CLB, Amsterdam, The Netherlands) were fixed on the 96-microwell plates by incubating the wells with 50 μ l of mAb solution (CLB-CD28; CLB, Amsterdam, The Netherlands) 50 μ l (1/650 dilution in culture medium) was added directly to the wells. Further, 20 μ l PMA (Sigma, St. Louis, MO, USA) solution (final concentration: 0.5 ng/ml) was added. Subsequently, 20 μ l of immunosuppressants were added by serial dilution in triplicate wells. Finally 100 μ l of the T cell suspension (10^6 /ml) was added. After 48-hour incubation at 37°C in 5% CO₂ 20 μ l BrdU (100 μ M solution) (Cell Proliferation Elisa, Boehringer-Mannheim Belgium) was added to each well. After a further overnight incubation the T cell proliferation was measured using a colorimetric immunoassay for qualification of cell proliferation based on measurements of the incorporation of BrdU during DNA synthesis. The optical density (OD) was measured by a Behring EL311 plate reader at 450 nm (reference wavelength: 690 nm). The percent suppression of proliferation by drugs was counted using the formula:

$$35 \quad \text{Per cent inhibition} = \frac{(\text{OD+drugs}) - (\text{OD Cult. Med.})}{(\text{OD+drugs}) - (\text{OD Cult. Med.})} \times 100$$

- 40 In vitro immunosuppressive effect of Xanthine Derivatives as measured with the MLR and with tests involving polyclonal T cell proliferation induced by anti-CD3 mAb + PMA or anti-CD28 mAb + PMA (table VI)

[0032]

- 45 - In the table VI column II shows the IC50 values of the various substances in the MLR. The IC50 value represents the lowest concentration of the substances that resulted in a 50% suppression of the MLR.
- Column III shows the IC50 value of the various substances for the anti-CD3 mAb + PMA pathway and row IV the IC50 values of the various substances for the anti-CD28 mAb + PMA pathway.
- As a comparison the values of other immunosuppressants: CsA, FK506, Rapamycin, Leflunomide and Mycophenolic acid are given as well.

- [0033] Whole Blood Assay (WBA): WBA is a lymphoproliferation assay performed in vitro but using lymphocytes present in whole blood, taken from animals that were previously given test substances in vivo. Hence it reflects the in vivo effect of substances as assessed with an in vitro read-out assay.

- 50 [0034] Rats: inbred, male 6- to 8-weeks old R/A rats weighing \pm 200 g were used as recipients.

- [0035] Drug administration: Xanthine derivatives were dissolved in DMSO and further diluted with PBS. Products were given orally in different concentrations 2 times a day for 2 days. To perform the experiments, 6-8 hours after the last administration 1 ml of blood is taken by heart puncture after ether anesthesia and anticoagulated with 100 U/ml of

EP 0 956 855 A1

preservative free heparine.

[0036] Whole Blood Assay: This assay was performed as we described previously [Use of the Methylxanthine Derivatives A802715 in Transplantation Immunology. II In vitro Experiments. (Yuan Lin, et al., Transplantation 1997, 63, No. 12, 1734-1738)].

5 [0037] Heparinized whole blood was diluted (1:25) with complete RPMI medium and stimulated with 15 µg/ml of concanavalin A (Con A) in triplicate wells in 96-well microtiter plates at 37°C and 5% CO₂. After 96-h culture, proliferation was determined by measuring the incorporation (cpm) of [³H]-thymidine.

[0038] The Con A induced proliferation of lymphocytes taken from rats receiving the test substances (exp) was compared with that from rats receiving only the solvent (con). The percent suppression was calculated as follows:

10

$$\% \text{ sup pression} = 100 - \left[\frac{\text{cpm exp}}{\text{cpm con}} \times 100 \right]$$

15

Results			
Nr	% suppression	Administration of drugs	Blood taken after:
11	33	40mg/kg/d 2x/d 2d	8 h
14	86	40mg/kg/d 2x/d 2d	8 h

25 [0039] First, most of the substances according to the invention have a clear suppressive effect in the MLR (mixed lymphocyte reaction). The MLR is considered as an in vitro analogue of the transplant rejection as it is based on the recognition of allogeneic MHC (major histocompatibility antigens) on the stimulator leucocytes, by responding lymphocytes. Various established immunosuppressive drugs are known to suppress the MLR, and were also shown in this description. Further, the 8-substituted xanthine derivatives are more effective than the non-substituted.

30 [0040] From these data it can be deduced that the 8-substituted xanthine derivatives may be effective in clinical situations where other immunosuppressants are active as well.

[0041] These include the prevention and/or treatment of organ transplant rejection, the prevention and/or treatment of both rejection and the occurrence of graft-versus-host-disease after BM transplantation; the prevention and/or treatment of autoimmune diseases including diabetes mellitus, multiple sclerosis, glomerulonephritis, rheumatoid arthritis, psoriasis systemic diseases such as vasculitis; scleroderma, polymyositis, autoimmune endocrine disorders (thyroiditis), ocular diseases (uveitis), inflammatory bowel diseases (Crohn's disease, colitis ulcerosa), autoimmune liver diseases (autoimmune hepatitis, primary biliary cirrhosis) autoimmune pneumonitis and auto-immune carditis.

[0042] Whereas cyclosporine A and FK506 are only active in the anti-CD3 + PMA test, the 8-substituted xanthine derivatives according to the invention were active, not only in the anti-CD3 + PMA but also in the anti-CD28 + PMA test.

40 [0043] It has been shown that the latter is Ca-calcmodulin resistant, and resistant to CsA and FK506. The anti-CD28 + PMA pathway has also been called the cosignal pathway and is important to induce energy and even tolerance in T cells. Moreover, representative compounds have been found to be active in a whole blood assay.

[0044] Under the term "organ" in the description is understood all organs or parts of organs (even several) in mammals, in particular humans, for example kidney, heart, skin, liver, muscle, cornea, bone, bone marrow, lung, pancreas, intestine or stomach.

[0045] After organ transplantation, rejection of the transplanted organ by the recipient occurs (host-versus-graft reaction). After bone marrow transplantation, also rejection of the host by the grafted cell may occur (graft-versus-host reaction). Rejection reactions mean all reactions of the recipient body or of the transplanted organ which in the end lead to cell or tissue death in the transplanted organ or adversely affect the functional ability and viability of the transplanted organ or adversely affect the functional ability and viability of the transplanted organ or the recipient. In particular, this means acute and chronic rejection reactions.

[0046] Auto-immune disorders include, inter alia, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, pemphigus, atopic dermatitis, myositis, multiple sclerosis, nephrotic syndrome (in particular glomerulonephritis), ulcerative colitis or juvenile diabetes.

55 [0047] The invention further relates to the use of cyclosporin A or FK506 or Rapamycin and at least one 8-substituted xanthine according to the invention for the production of a pharmaceutical for inhibiting the replication of viruses such as picorna-, toga-, bunya-, orthomyxo-, paramyxo-, rhabdo-, retro-, arena-, hepatitis B-, hepatitis C-, hepatitis D-, adeno-, vaccinia-, papilloma-, herpes-, varicella-zoster-virus or human immunodeficiency virus (HIV); or for treating of

EP 0 956 855 A1

cancer such as lung cancers, leukaemia, ovarian cancers, sarcoma, Kaposi's sarcoma, meningioma, colon cancers, lymph node tumors, glioblastoma multiforme, prostate cancers or skin carcinoses.

[0047] The invention further relates to the use of cyclosporin A or FK506 or rapamycin and at least one xanthine of the general formula for the production of a pharmaceutical for the treatment of human after organ transplantation or of (auto)immune disorders.

[0048] Hence, the advantage to associate xanthine with other immunosuppressants may be that, first, the therapeutic spectrum of action of the individual components is quantitatively and qualitatively broadened. Secondly that it allows, by means of a dose reduction without reduced efficacy but with increased safety, that the treatment of immune disorders which were hitherto no indication for immunosuppressive therapy as a result of side effects may be considered. At the same time, the therapy costs can be decreased to an appreciable extent.

[0049] The preferred compounds according to the invention are the xantine derivates bearing on the 8-position a substituted or unsubstituted phenyl.

19

20

25

30

35

40

45

50

55

EP 0 956 855 A1

6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
359
360
361
362
363
364
365
366
367
368
369
369
370
371
372
373
374
375
376
377
378
379
379
380
381
382
383
384
385
386
387
388
389
389
390
391
392
393
394
395
396
397
398
399
399
400
401
402
403
404
405
406
407
408
409
409
410
411
412
413
414
415
416
417
418
419
419
420
421
422
423
424
425
426
427
428
429
429
430
431
432
433
434
435
436
437
438
439
439
440
441
442
443
444
445
446
447
448
449
449
450
451
452
453
454
455
456
457
458
459
459
460
461
462
463
464
465
466
467
468
469
469
470
471
472
473
474
475
476
477
478
479
479
480
481
482
483
484
485
486
487
488
489
489
490
491
492
493
494
495
496
497
498
499
499
500
501
502
503
504
505
506
507
508
509
509
510
511
512
513
514
515
516
517
518
519
519
520
521
522
523
524
525
526
527
528
529
529
530
531
532
533
534
535
536
537
538
539
539
540
541
542
543
544
545
546
547
548
549
549
550
551
552
553
554
555
556
557
558
559
559
560
561
562
563
564
565
566
567
568
569
569
570
571
572
573
574
575
576
577
578
579
579
580
581
582
583
584
585
586
587
588
589
589
590
591
592
593
594
595
596
597
598
599
599
600
601
602
603
604
605
606
607
608
609
609
610
611
612
613
614
615
616
617
618
619
619
620
621
622
623
624
625
626
627
628
629
629
630
631
632
633
634
635
636
637
638
639
639
640
641
642
643
644
645
646
647
648
649
649
650
651
652
653
654
655
656
657
658
659
659
660
661
662
663
664
665
666
667
668
669
669
670
671
672
673
674
675
676
677
678
679
679
680
681
682
683
684
685
686
687
688
689
689
690
691
692
693
694
695
696
697
698
699
699
700
701
702
703
704
705
706
707
708
709
709
710
711
712
713
714
715
716
717
718
719
719
720
721
722
723
724
725
726
727
728
729
729
730
731
732
733
734
735
736
737
738
739
739
740
741
742
743
744
745
746
747
748
749
749
750
751
752
753
754
755
756
757
758
759
759
760
761
762
763
764
765
766
767
768
769
769
770
771
772
773
774
775
776
777
778
779
779
780
781
782
783
784
785
786
787
788
789
789
790
791
792
793
794
795
796
797
798
799
799
800
801
802
803
804
805
806
807
808
809
809
810
811
812
813
814
815
816
817
818
819
819
820
821
822
823
824
825
826
827
828
829
829
830
831
832
833
834
835
836
837
838
839
839
840
841
842
843
844
845
846
847
848
849
849
850
851
852
853
854
855
856
857
858
859
859
860
861
862
863
864
865
866
867
868
869
869
870
871
872
873
874
875
876
877
878
879
879
880
881
882
883
884
885
886
887
888
889
889
890
891
892
893
894
895
896
897
898
899
899
900
901
902
903
904
905
906
907
908
909
909
910
911
912
913
914
915
916
917
918
919
919
920
921
922
923
924
925
926
927
928
929
929
930
931
932
933
934
935
936
937
938
939
939
940
941
942
943
944
945
946
947
948
949
949
950
951
952
953
954
955
956
957
958
959
959
960
961
962
963
964
965
966
967
968
969
969
970
971
972
973
974
975
976
977
978
979
979
980
981
982
983
984
985
986
987
988
989
989
990
991
992
993
994
995
996
997
997
998
999
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1098
1099
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1198
1199
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1298
1299
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1398
1399
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1498
1499
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1598
1599
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1698
1699
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1798
1799
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1889
1890
1891
1892
1893
1894
1895

EP 0 956 855 A1

Compound n°	R ₁	R ₂	R ₃	R ₄	Z ₁	Z ₂
16	CH ₃ CH ₂ CH ₃	CH ₃ CH ₂ CH ₃	H	H	S	SO ₃ Na
17	CH ₃	CH ₃	H	S	O	
18	CH ₃	CH ₃	H	S	S	
19	CH ₃	CH ₃	CH ₃	O	O	
20	CH ₃	CH ₃	CH ₃	S	O	
21	CH ₃ CH=CH ₂	CH ₃	CH ₃	O	O	
22	-CH ₂ COOH	CH ₃	CH ₃	O	O	
23	-CH ₂ COOH	CH ₃	CH ₃	O	O	
24	-CH ₂ OOEt	CH ₃	CH ₃	O	O	
25	-CH ₂ CHON-CH ₃	CH ₃	CH ₃	O	O	
26	-CH ₂ CHON-CH ₃	CH ₃	CH ₃ CH ₂ CH ₃	O	O	
28	-CH ₂ CH ₂ CH ₃	CH ₃ CH ₂ CH ₃	H		-OCH ₂ COOH	
29	-CH ₂ CH ₂ CH ₃	CH ₃ CH ₂ CH ₃	H		-OCH ₂ COOEt	
30	CH ₃ CH ₂ CH ₃	CH ₃ CH ₂ CH ₃	H		OCH ₂ COOEt	
31	CH ₃ CH ₂ CH ₃	CH ₃ CH ₂ CH ₃	H		OCH ₂ CONH(CH ₂) ₂ NHCOCH ₃	
32	CH ₃ CH ₂ CH ₃	CH ₃ CH ₂ CH ₃	H		OCH ₂ CONH(CH ₂) ₂ NH ₂ SO ₃ H	

EP 0 956 855 A1

Compound #	R ₁	R ₂	R ₃	R ₄	Y	Z ₁
33	CH ₂ CH ₂ CH ₃	CH ₂ CH ₂ CH ₃	H	H	0	OCH ₂ CONH(CH ₂) ₂ NH ₂
34	CH ₂ CH ₂ CH ₃	CH ₂ CH ₂ CH ₃	H	H	0	OCH ₂ CONH(CH ₂) ₂ NH ₂
35	CH ₂ CH ₂ CH ₃	CH ₂ CH ₂ CH ₃	H	H	0	OCH ₂ CONH(CH ₂) ₂ NH ₂
36	CH ₂ CH ₂ CH ₃	CH ₂ CH ₂ CH ₃	H	CH ₃	0	SO ₂ NH ₂
37	H	H	CH ₃	CH ₃	0	SO ₂ H
38	H	CH ₃	CH ₃	H	0	SO ₂ NH(CH ₂) ₂ NH ₂
39	CH ₂ CH ₂ CH ₃	CH ₂ CH ₂ CH ₃	CH ₃	H	0	SO ₂ NH(CH ₂) ₂ NH ₂
40	CH ₂ CH ₂ CH ₃	CH ₂ CH ₂ CH ₃	CH ₃	H	0	SO ₂ NH(CH ₂) ₂ NH ₂
41	CH ₃	CH ₃	CH ₃	H	0	SO ₂ NH(CH ₂) ₂ NH ₂
42	CH ₃	CH ₃	CH ₃	H	0	SO ₂ NH(CH ₂) ₂ NH ₂
43	CH ₃	CH ₃	CH ₃	H	0	SO ₂ NH(CH ₂) ₂ NH ₂
44	CH ₃	CH ₃	CH ₃	H	S	SO ₂ NH(CH ₂) ₂ NH ₂
45	CH ₃	CH ₃	CH ₃	H	S	SO ₂ NH(CH ₂) ₂ NH ₂
46	CH ₂ CH ₃	CH ₂ CH ₃	CH ₂ CH ₃	H	S	SO ₂ NH(CH ₂) ₂ NH ₂

EP 0 956 855 A1

EP 0 956 855 A1


Compound n*	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆	R ₇	R ₈	R ₉	R ₁₀	R ₁₁	R ₁₂	R ₁₃	R ₁₄	R ₁₅	R ₁₆	R ₁₇	R ₁₈	R ₁₉	R ₂₀	R ₂₁	R ₂₂	
61	CH ₂ CH ₂ CH ₃	CH ₃ CH ₂ CH ₃	CH ₃	CH ₃	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H
62	CH ₃	CH ₃	CH ₃ CH ₂ CH ₃	CH ₃ CH ₂ CH ₃																			
63	CH ₃ CH ₂ CH ₃	CH ₃ CH ₂ CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	
64	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	
65	CH ₃ CH ₂ CH ₃	CH ₃ CH ₂ CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	
66	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	
67	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	
68	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	
69	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	
70	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H
71	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	
72	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	
73	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	
74	CH ₃ CH ₂ CH ₃	CH ₃ CH ₂ CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	
75	CH ₃ CH ₂ CH ₃	CH ₃ CH ₂ CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	
76	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	
77	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	
78	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	
79	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	
80	CH ₃ CH ₂ CH ₃	CH ₃ CH ₂ CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	
81	CH ₃ CH ₂ CH ₃	CH ₃ CH ₂ CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	
82	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	

EP 0 956 855 A1

Compound n°	R ₁	R ₄	Z ₀											
			CH ₃	CH ₃ CH ₂ CH ₃	CH ₃ CH ₂ CH ₂ CH ₃	CH ₃ CH ₂ CH ₂ CH ₂ CH ₃	CH ₃ CH=CH ₂	CH ₃ CH=CHCH ₃	CH ₃ CH ₂ CH=CH ₂	CH ₃ CH ₂ CH ₂ CH=CH ₂	CH ₃ CH ₂ CH ₂ CH ₂ CH=CH ₂	CH ₃ CH ₂ CH ₂ CH ₂ CH ₂ CH=CH ₂	CH ₃ CH ₂ CH ₂ CH ₂ CH ₂ CH ₂ CH=CH ₂	
Z ₁														
83	H	CH ₃												
112	CH ₃	CH ₃												
113	CH ₃ CH ₂ CH ₃	CH ₃ CH ₂ CH ₃												
114	CH ₃ CH=CH ₂	-CH ₃ CH ₂ CH ₃												
115	CH ₃	CH ₃	H											
116	CH ₃ CH ₂ CH ₃	CH ₃ CH ₂ CH ₃												
117	CH ₃ CH=CH ₂	CH ₃ CH ₂ CH ₃												
118	CH ₃ CH ₂ CH ₃	CH ₃ CH ₂ CH ₃												
119	CH ₃ CH=CH ₂	CH ₃ CH ₂ CH ₃												
125	CH ₃	CH ₃	H											

EP 0 956 855 A1

Table II

						
	R ₁	R ₂	R ₃	Z ₁	Z ₂	Mp
1a	H	CH ₃	CH ₃	H	-	
1	HC=C-CH ₂	CH ₃	CH ₃	H	-	204°
2a	H	CH ₃	H	H	-	
2	HC=C-CH ₂	CH ₃	HC=C-CH ₂	H	-	177°
3a	CH ₃	H	H	H	-	
3	CH ₃	HC=C-CH ₂	HC=C-CH ₂	H	-	174°
4a	H	H	CH ₃	H	-	
4	HC=C-CH ₂	HC=C-CH ₂	CH ₃	H	-	172°
5a	H	H	H	H	-	
5	HC=C-CH ₂	HC=C-CH ₂	HC=C-CH ₂	H	-	155°
22	HOOC(CH ₂) ₆	CH ₃	CH ₃	H	-	195°
23	HOOC(CH ₂) ₅	CH ₃	CH ₃	H	-	208-210°
24	EtOOOC(CH ₂) ₃	CH ₃	CH ₃	H	-	86-88°
67a	CH ₃	H	CH ₃	H	-	
67	CH ₃	HC=C-CH ₂	CH ₃	H	-	
68a	H	CH ₂ C(CH ₃) ₃	H	H	-	
68	CH ₃	CH ₂ C(CH ₃) ₃	CH ₃	H	-	158°
82a	CH ₃	CH ₃	H	-C ₆ H ₄ -	p-CF ₃	
82	CH ₃	CH ₃	CH ₂ =CHCH ₃	-C ₆ H ₄ -	p-CF ₃	116-118°
112a	CH ₃	CH ₃	H	-C ₆ H ₅	-	
112	CH ₃	CH ₃	CH ₂ CH ₂ CH ₂	-C ₆ H ₅	-	141°
113a	H	CH ₂ CH ₂ CH ₃	H	-C ₆ H ₅	-	
113	CH ₂ CH ₂ CH ₃	CH ₂ CH ₂ CH ₃	CH ₂ CH ₂ CH ₂	-C ₆ H ₅	-	123-125°
114a	H	CH ₂ CH ₂ CH ₃	H	-C ₆ H ₅	-	
114	CH ₂ =CHCH ₃	CH ₂ CH ₂ CH ₃	CH ₂ =CHCH ₂	-C ₆ H ₅	-	113-114°
116a	H	CH ₂ CH ₂ CH ₃	H	-C ₆ H ₄	p-C ₆ H ₅	
116	CH ₂ CH ₂ CH ₃	CH ₂ CH ₂ CH ₃	CH ₂ CH ₂ CH ₂	-C ₆ H ₄	p-C ₆ H ₅	116°

55

EP 0 956 855 A1

	R ₁	R ₂	R ₃	Z ₁	Z ₂	Mp
s	117a H	CH ₃ CH ₂ CH ₂	H	-C ₆ H ₄	p-C ₆ H ₅	
	117 CH ₂ =CHCH ₂	CH ₃ CH ₂ CH ₂	CH ₂ =CHCH ₂	-C ₆ H ₄	p-C ₆ H ₅	104-106°
	118a H	CH ₃ CH ₂ CH ₂	H	-C ₆ H ₄	p-Cl	
10	118 CH ₃ CH ₂ CH ₂	CH ₃ CH ₂ CH ₂	CH ₃ CH ₂ CH ₂	-C ₆ H ₄	p-Cl	71-74°
	119a H	CH ₃ CH ₂ CH ₂	H	-C ₆ H ₄	p-Cl	
	119 CH ₂ =CHCH ₂	CH ₃ CH ₂ CH ₂	CH ₂ =CHCH ₂	-C ₆ H ₄	p-Cl	89-91°

15

20

Table III

	R ₁	R ₂	R ₃	X	Z ₁	Z ₂	Mp
	16 CH ₃ CH ₂ CH ₂	CH ₃ CH ₂ CH ₂	H	S	-C ₆ H ₄	p-SO ₂ NH ₂	>300°
25	25 CH ₃ CHOH(CH ₂) ₄	CH ₃	CH ₃				118-120°
	26 CH ₃ CHOH(CH ₂) ₄	CH ₂	CH ₃ CH ₂ CH ₂				72-74°
	52 CH ₃	CH ₃	H	O	-C ₆ H ₄	p-NO ₂	275°
	53 CH ₃ CH ₂ CH ₂	CH ₃ CH ₂ CH ₂	H	O	-C ₆ H ₄	p-NO ₂	>270°
30	54 CH ₃ CH ₂ CH ₂	CH ₃ CH ₂ CH ₂	H	O	-C ₆ H ₄	p-NO ₂	>300°
	69 CH ₃	CH ₂ C(CH ₃) ₃	H	O	H	.	234°
	70 H	CH ₂ C(CH ₃) ₃	CH ₃	O	H	.	248°
35	71 CH ₃	CH(CH ₃) ₂	H	O	H	.	230°
	115 CH ₃	CH ₃	H	O	-C ₆ H ₄	p-C ₆ H ₅	>300°

40

45


50

55

EP 0 956 855 A1

5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100

Table IV



R	R ¹	R ²	X	R				R ¹	R ²	X	Z	Mp.	
				n-Pr	Me	H	S						
16a	n-Pr	n-Pr	H	16a	n-Pr	n-Pr	H	n-Pr	Me	H	S	p-C ₆ H ₄ SO ₂ NH ₂	268-270°
52a	Me	Me	H	52a	Me	Me	H	n-Pr	Me	H	O	p-C ₆ H ₄ NO ₂	>250° dec
53a	n-Pr	n-Pr	H	53a	n-Pr	n-Pr	H	n-Pr	Me	H	O	p-C ₆ H ₄ NH ₂	235-237°
54a	CH ₂ CMes ₂	Me	H	54a	n-Pr	CH ₂ CMes ₂	H	n-Pr	Me	H	O	H	267-270°
69a	CHMe ₂	Me	H	69a	CH ₂ CMes ₂	CH ₂ CMes ₂	H	CH ₂ CMes ₂	CH ₂ CMes ₂	H	O	H	288-290°
71b	CHMe ₂	Me	H	71b	CH ₂ CMes ₂	CH ₂ CMes ₂	H	CH ₂ CMes ₂	CH ₂ CMes ₂	H	O	H	269-272°
70b	CH ₂ CMes ₂	Me	H	70a	CH ₂ CMes ₂	CH ₂ CMes ₂	H	CH ₂ CMes ₂	CH ₂ CMes ₂	H	O	H	180°
116b	n-Pr	n-Pr	H	116b	n-Pr	n-Pr	H	n-Pr	Me	H	O	2-phenyl-1-phenylpropyl	180°
115a	Me	Me	H	115a	Me	Me	H	Me	Me	H	O	2-phenyl-1-phenylpropyl	180°
118b	n-Pr	n-Pr	H	118b	n-Pr	n-Pr	H	n-Pr	Me	H	O	2-phenyl-1-phenylpropyl	269-272°

EP 0 956 855 A1

Table V

R	R'	X	M.p.				
			CH ₃ COMe	CH ₃ COMe	R ¹	R ³	X
70c	CH ₃ COMe	H	70b	H	Me	0	>237° dec
69c	CH ₃ COMe	Me	69b	Me	H	0	108-110°
16c	n-Pr	n-Pr	16b	n-Pr	H	S	110-113°
52c	Me	Me	52b	Me	H	0	
53c	n-Pr	n-Pr	53b	n-Pr	H	0	
71c	CH ₃ Me ₂	Me	71b	CH ₃ Me ₂	Me	H	0
116d	n-Pr	H	116c	n-Pr	H	H	0

EP 0 956 855 A1

Table VI

5	Nr	IC50 in μ M			IC50 in μ M			
		Xanthine derivatives			Xanthine derivatives			
		MLR	aCD3	aCD28	MLR	aCD3	aCD28	
10	1	> 200	150	> 200	25	> 200	140	160
	2	> 200	> 200	100	26	100	100	100
	3	150	150	100	28	120	150	75
	4	> 200	90	> 200	29	> 200	150	130
15	5	> 200	50	> 200	30	> 200	140	100
	8	30	35	80	31	200	120	80
	9	25	40	50	32	70	90	110
	10	50	20	30	33	160	45	35
20	11	25	40	55	34	105	45	60
	12	30	90	80	35	50	50	70
	13	ND	35	40	36	> 200	45	40
	14	15	40	35	37	> 200	150	150
25	15	ND	> 200	170	38	> 200	120	120
	16	ND	25	20	39	100	120	140
	17	80	30	40	40	25	60	70
	18	120	75	40	41	120	80	90
30	19	ND	50	80	42	170	130	130
	20	ND	170	50	43	115	120	90
	21	ND	180	80	44	120	170	120
	22	> 200	> 200	> 200	45	165	25	25
35	23	> 200	> 200	> 200	46	> 200	25	20
	24	> 200	170	150				

45

50

55

EP 0 956 855 A1

5	Nr			IC50 in μ M		
	Xanthine derivatives					
	MLR	aCD3	aCD28			
10	47	200	140	140		
	48	180	160	150		
	49	ND	ND	ND		
	50	180	200	120		
15	51	200	200	200		
	52	80	180	90		
	53	110	160	110		
20	54	120	130	130		
	55	> 200	200	120		
	56	> 200	170	100		
	57	> 200	> 200	180		
25	58	> 200	160	170		
	59	15	155	135		
	60	> 200	200	190		
30	61	100	170	110		
	62	> 200	> 200	190		
	63	> 200	135	100		
35	64	> 200	> 200	> 200		
	65	> 200	135	75		
	66	> 200	170	170		
	67	> 200	> 200	200		
40	68	75	130	120		
	69	120	110	45		
	70	> 200	180	140		
45	71	160				

50

55

EP 0 956 855 A1

5	I.S.	IC50		
	Immunosuppressant			
10		MLR	aCD3	aCD28
	CyA	20 nM	50 nM	N.S.
	FK506	1 nM	1 nM	N.S.
	Rapamycin	1 nM	1 nM	1 nM
15	Leflunomide	25 μ M	15 μ M	20 μ M
	Mofetil	<0.5 μ M	50 nM	50 nM

20


N.S. = not suppressive even not in the highest
concentration

25

30 Claims

1. Use of a xanthine derivative of general formula (I):

35



45

wherein:

50

R₁, R₂ and R₃ are independently hydrogen, saturated or unsaturated aliphatic chains which may be straight or branched having 1 to 6 carbon atoms;

X and Y are independently oxygen or sulfur;

55

Z₁ is selected from the group comprising a thienyl; furanyl; cyclopentyl, phenyl or a substituted by Z₂ or unsubstituted phenyl; wherein Z₂ is selected from the group comprising phenyl; sulfonic acid; unsubstituted or N-substituted sulfonamide with substituents such as alkyl, aminalkyl where the amino group may be substituted itself with lower alkyl groups bearing 1 to 4 carbon atoms; nitro; halogen substituted or unsubstituted amino group; aliphatic chain with 1 to 8 carbon atoms; halogenated aliphatic chain with 1 to 3 carbon atoms; aliphatic chain containing ether functions; acids, esters, amides, substituted or unsubstituted amines having 1 to 3 carbon atoms; nitro, sulfonamides or a combination of these functional groups with a maximum length of the chain of 12 atoms,

or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of auto-

EP 0 956 855 A1

immuno disorders.

2. Use according to claim 1, wherein

5 R_1 , R_2 and R_3 are independently hydrogen; saturated or unsaturated straight aliphatic chains having 1 to 3 carbon atoms; and
 Z_1 is a substituted or unsubstituted phenyl.

3. Use according to claim 1 or 2, wherein the xanthine derivative is compound selected from the group comprising:

10 1,7-dialyl-3-methyl-8-phenylxanthine (8);
1,3-dipropyl-8-[4(dimethylamino(ethyl)amino(sulfonyl))fenyl]xanthine (9);
1,3,7-trimethyl-8-(4-trifluoromethylfenyl)xanthine (10);
13 1,3-dipropyl-8-[4(diethylamino(propyl)amino(sulfonyl))fenyl]xanthine (11);
1,3-dipropyl-2-thio-8-[4(((N-2-aminoethyl)amino)carbonyl)methyl]oxy(fenyl)xanthine (35);
1,3-dipropyl-8-[4-(dimethylamino(propyl)amino(sulfonyl))fenyl]xanthine (40);
1,3-dimethyl-7-propyl-8-phenylxanthine (112);
17 1,7-dialyl-3-propyl-8-(p-bifeny) xanthine (117);
1,3,7-tripropyl-8-(4-chlorofenyl)xanthine (118);
20 1,7-dialyl-3-propyl-8-(4-chlorofenyl)xanthine (119).

4. Product containing a compound according to any of the preceding claims 1-3 and at least a compound selected from the group comprising cyclosporine A, FK506, Rapamycin, Leflunomide, Mofetil.

25 5. Use of a product according to claim 4, as a combined preparation for simultaneous separate or sequential use in the treatment of auto-immuno disorders.

6. Compound having the formula:

30 1-propynyl-3,7-dimethylxanthine (1);
1,7-dipropynyl-3-methylxanthine (2);
1-methyl-3,7-dipropynylxanthine (3);
1,3-dipropynyl-7-methylxanthine (4);
1,8,7-tripropynylxanthine (5);
35 1-(4-carboxybutyl)-3,7-dimethylxanthine (22);
1-(3-carboxypropyl)-3,7-dimethylxanthine (23);
1-(3-ethoxycarbonyl)propyl-3,7-dimethylxanthine (24);
1,7-dimethyl-3-propynylxanthine (67);
1,7-dimethyl-3-((tertbutyl)methyl)xanthine (68);
40 1,3-dimethyl-7-allyl-8-[4-trifluoromethyl]fenyl]xanthine (82);
1,3-dimethyl-7-propyl-8-phenylxanthine (112);
1,3,7-tripropyl-8-phenylxanthine (113);
1,7-dialyl-3-propyl-8-phenylxanthine (114);
1,3,7-tripropyl-8-(p-bifeny) xanthine (116);
45 1,7-dialyl-3-propyl-8-(p-bifeny) xanthine (117);
1,3,7-tripropyl-8-(4-chlorofenyl)xanthine (118);
1,7-dialyl-3-propyl-8-(4-chlorofenyl)xanthine (119).

7. Compound having the formula:

50 1-propynyl-3,7-dimethylxanthine (1);
1,7-dipropynyl-3-methylxanthine (2);
1-methyl-3,7-dipropynylxanthine (3);
1,3-dipropynyl-7-methylxanthine (4);
55 1,3,7-tripropynylxanthine (5).

8. Compound having the formula:

EP 0 956 855 A1

1-(4-carboxybutyl)-3,7-dimethylxanthine (22);
1-(3-carboxypropyl)-3,7-dimethylxanthine (23);
1-(3-ethoxycarbonyl)propyl-3,7-dimethylxanthine (24).

5 9. Compound having the formula:

1,3-dimethyl-7-allyl-8-[(4-trifluoromethyl)fenyl]xanthine (82);
1,3-dimethyl-7-propyl-8-fenylxanthine (112);
1,3,7-tripropyl-8-fenylxanthine (113);
10 1,7-diallyl-3-propyl-8-fenylxanthine (114);
1,3,7-tripropyl-8-(p-bifeny) xanthine (116).

10 10. Compound having the formula:

15 1,7-diallyl-3-propyl-8-(p-bifeny) xanthine (117);
1,3,7-tripropyl-8-(4-chlorofenyl) xanthine (118);
1,7-diallyl-3-propyl-8-(4-chlorofenyl) xanthine (119).

20 11. Use of a compound according to any of the claims 7-10, for the manufacture of a medicament for the treatment of
auto-immuno disorders.

25

30

35

40

45

50

55

EP 0 956 855 A1

European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 98 20 1323

DOCUMENTS CONSIDERED TO BE RELEVANT									
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.)						
A	WD 96 36638 A (CHIROSCIENCE LTD) 21 November 1996		A61K31/52 C07D473/06 C07D473/10						
A	EP 0 490 181 A (HOEST-ROUSSEL) 17 June 1992								
A	M.H. HOLSBACH ET AL.: "Al adenosine receptor antagonists as ligands for positron emission tomography and single-photon emission tomography." J. MED. CHAM., vol. 41, no. 4, 1998, pages 555-563, XP002078914								
A	I.A. DOICHINOVA ET AL.: "QSAR studies of 8-substituted xanthines as adenosine receptor antagonists." EUR. J. MED. CHEM., vol. 29, no. 2, 1994, pages 133-138, XP000574700								
A	C.E. MÜLLER ET AL.: "Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: SAR at adenosine receptor." J. MED. CHEM., vol. 36, no. 22, 1993, pages 3341-3349, XP000574701		TECHNICAL FIELDS SEARCHED (Int.Cl.) A61K C07D						
A	M.T. SHAMIN ET AL.: "Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di- and trisubstituted alkylxanthines with substitution at the 1-, 3- and 7-positions." J. MED. CHEM., vol. 32, no. 6, 1989, pages 1231-1237, XP002078917								
<p>The present search report has been drawn up for all claims</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 33%;">Place of search</td> <td style="width: 33%;">Date of completion of the search</td> <td style="width: 34%;">Examiner</td> </tr> <tr> <td>THE HAGUE</td> <td>29 September 1998</td> <td>Klaver, T</td> </tr> </table> <p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on or after the filing date D : document cited in the application L : document cited for other reasons</p> <p>S : member of the same patent family, corresponding document</p>				Place of search	Date of completion of the search	Examiner	THE HAGUE	29 September 1998	Klaver, T
Place of search	Date of completion of the search	Examiner							
THE HAGUE	29 September 1998	Klaver, T							